Molnupiravir Merck

MRK and Ridgeback Biotherapeutics Friday announced positive interim analysis of Phase 3 MOVe-OUT trial of molnupiravir MK-4482 EIDD-2801 in at risk. If the drug proves safe and effective Merck says i…